New Recruiting Trial: Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
WHY IT MATTERS
This trial offers a potential new treatment option for patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer with limited treatment alternatives after standard therapies fail.
Researchers are testing a new drug called Xaluritamig to treat Ewing sarcoma, a rare bone cancer that has come back or stopped responding to previous treatments. This is an early-stage study (Phase 1) that will include children, teenagers, and adults. The study is now accepting patients and is expected to start in April 2026.
NCT ID: NCT07297979 Title: Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) Status: RECRUITING Phase: PHASE1 Sponsor: Amgen Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07297979 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you or your child has relapsed or refractory Ewing sarcoma, ask your oncologist about eligibility for this trial or visit clinicaltrials.gov/study/NCT07297979 to learn more about enrollment locations and requirements.